Clover Health Tops Q3 Estimates With $759M Revenue and $16M Adjusted EBITDA
CLOV has more than doubled off its 52-week low of $1.58.
Summary
Clover Health beat on both lines in Q3: revenue of $759M came in above the $738.4M IBES estimate, and adjusted EBITDA of $16M nearly doubled the $9.31M consensus. Net income was $6M, a swing to profit versus the year-ago loss and a step down from Q2's $28.0M profit. The print follows a strong Q2 that showed membership up 49% and a $28.0M net profit, and an October CMS award of 5 Stars for the 2027 PPO Medicare Advantage plans, up from 4.5 Stars. Clover also raised its 2026 guidance, now calling for revenue of $2.97B-$3.00B, GAAP net income of $25M-$35M, gross profit of $540M-$555M, adjusted EBITDA of $75M-$85M and average MA membership of 157,000-158,000, and it expects its first full-year GAAP profit. Beating on revenue and EBITDA with positive net income supports the margin-improvement story the market has been paying for. Watch whether the Q2-to-Q3 net income decline reflects seasonality or rising medical costs when management details the quarter.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Clover raised 2026 guidance: revenue $2.97B-$3.00B, GAAP net income $25M-$35M, gross profit $540M-$555M, adjusted EBITDA $75M-$85M, average MA membership 157,000-158,000.
At the time of this announcement, CLOV was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $1.58 to $5.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.